Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia

European Journal of Internal Medicine

Volumn 20, Issue 5, 2009, Pages 540-544

  Metan, Gokhan ^a   Sariguzel, Fatma ^a   Sumerkan, Bulent ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Acinetobacter calcoaceticus Acinetobacter baumannii complex; Bacteraemia; Carbapenem resistance; Inappropriate therapy; Mortality; Turkey

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CIPROFLOXACIN; COLISTIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTION; ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENDEMIC DISEASE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; SURVIVAL; TERTIARY HEALTH CARE; TURKEY (REPUBLIC);

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TURKEY; YOUNG ADULT;

EID: 68949194579     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2009.05.005     Document Type: Article

References (35)

1. Maragakis L.L., and Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46 8 (2008) 1254-1263
2. Falagas M.E., Bliziotis I.A., and Siempos I.I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 10 2 (2006) R48
3. Flagas M.E., and Rafailidis P.I. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 11 3 (2007) 134
4. Korten V., Ulusoy S., Zarakolu P., Mete B., and Turkish MYSTIC Study Group. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program. Diagn Microbiol Infect Dis 59 4 (2007) 453-457
5. Metan G., Alp E., Aygen B., and Sümerkan B. Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J Antimicrob Chemother 60 1 (2007) 197-199
6. Alp E., Esel D., Yildiz O., Voss A., Melchers W., and Doganay M. Genotypic analysis of Acinetobacter bloodstream infection isolates in a Turkish university hospital. Scand J Infect Dis 38 5 (2006) 335-340
7. Kwon K.T., Oh W.S., Song J.H., Chang H.H., Jung S.I., Kim S.W., et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 59 3 (2007) 525-530
8. Chen P.H., Chen T.L., Lai C.H., Fung C.P., Wong W.W., Yu K.W., et al. Predictors of mortality in Acinetobacter baumannii bacteraemia. J Microbiol Immunol Infect 38 (2005) 127-136
9. Wareham D.W., Bean D.C., Khanna P., Hennessy E.M., Krahe D., Ely A., et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 27 7 (2008) 607-612
10. Falagas M.E., Kasiakou S.K., Rafailidis P.I., Zouglakis G., and Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 57 6 (2006) 1251-1254
11. Levry M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al., for the international sepsis definitions conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definition conference. Intensive Care Med 29 (2003) 530-538
12. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 3 (1988) 128-140
13. Gerner-Smidt P., Tjernberg I., and Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 29 2 (1991) 277-282
14. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Fifteenth Informational Supplement M100-S15 (2005), CLSI, Wayne, Pennsylvania, USA 6.1
15. Navon-Venezia S., Leavitt A., and Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59 4 (2007) 772-774
16. British Society for Antimicrobial Chemotherapy. BSAC disc diffusion method for antimicrobial susceptibility testing, version 6.1 (February 2007). http://www.bsac.org.uk [http://www.bsac.org.uk 22 January 2008, date last accessed]
17. Galani I., Kontopidou F., Souli M., Rekatsina P.D., Koratzanis E., Deliolanis J., et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 31 5 (2008) 434-439
18. Zhang J., and Yu K.F. What is the relative risk? A method for correcting the Odds Ratio in cohort studies of common outcomes. JAMA 280 19 (1998) 1690-1691
19. Grupper M., Sprecher H., Mashiach T., and Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteraemia. Infect Cont Hosp Epidemiol 28 3 (2007) 293-298
20. Koprnová J., Svetlanský I., Babel'a R., Bilíková E., Hanzen J., Zuscáková I., et al. Prospective study of antibacterial susceptibility, risk factors and outcome of 157 episodes of Acinetobacter baumannii bacteremia in 1999 in Slovakia. Scand J Infect Dis 33 12 (2001) 891-895
21. Lee N.Y., Lee H.C., Ko N.Y., Chang C.M., Shih H.I., Wu C.J., et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hospital Epidemiol 28 6 (2007) 713-719
22. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 1 (2008) 296-327
23. Gales A.C., Reis A.O., and Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39 1 (2001) 183-190
24. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., and Falagas M.E. Tigecycline for the treatment of multi-drug resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrobial Chemother 62 1 (2008) 45-55
25. Sung L.L., Yang D.I., Hung C.C., and Ho H.T. Evaluation of autoSCAN-W/A and Vitek GNI+AutoMicrobic system for identification of non-glucose fermenting Gram negative bacilli. J Clin Microbiol 38 3 (2000) 1127-1130
26. Snyder J.W., Munier G.K., and Johnson C.L. Direct comparison of BD Phoenix System with the MicroScan Walkaway System for identification and antimicrobial susceptibility testing of Enterobacteriaceae and nonfermentative Gram-negative organisms. J Clin Microbiol 46 7 (2008) 2327-2333
27. Falagas M.E., and Karveli E.A. The changing epidemiology of Acinetobacter baumannii infections: a development with major health public implications. Clin Microbiol Infect 13 (2007) 117-119
28. Gur D., Korten V., Unal S., Deshpande L.M., and Castanheira M. Increasing carbapenem resistance due to clonal dissemination of oxacillinase (OXA-23 and OXA-58) producing Acinetobacter baumannii: report from Turkish SENTRY Program sites. J Med Microbiol 57 (2008) 1529-1532
29. Hugonnet S., Chevrolet J.C., and Pittet D. The effect of workload on infection risk in critically ill patients. Crit Care Med 35 1 (2007) 76-81
30. Gur D., Gulay Z., Akan O.A., Aktaş Z., Kayacan C.B., Cakici O., et al. Resistance to newer beta-lactams and related ESBL types in Gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study. Mikrobiyol Bul 42 4 (2008) 537-544
31. Metan G., Zarakolu P., Cakir B., Hascelik G., and Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 26 (2005) 254-257
32. Karabay O., and Hosoglu S. Increased antimicrobial consumption following reimbursement reform in Turkey. J Antimicrobial Chemother 61 (2008) 1169-1171
33. Meric M., Kasap M., Gacar G., Budak F., Dundar D., Kolayli F., et al. Emergence and spread of carbapenem resistant Acinetobacter baumannii in a tertiary care hospital in Turkey. FEMS Microbiol Lett 282 2 (2008) 214-218
34. Vahapoglu H., Budak F., Kasap M., Gacar G., Torol S., Karadenizli A., et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp: co-existence with OXA-58 in multiple centres. J Antimicrobial Chemother 58 3 (2006) 537-542
35. Marque S., Poirel L., Heritier C., Brisse S., Blasco M.D., Filip R., et al. Regional occurrence of plasmid mediated carbapenem hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J Clin Microbiol 43 9 (2005) 4885-4888